Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Bex

Showing results (251-260 of 332) with videos related to

Pageof 34
Sort By:
The Journal of Urology|December 11, 2017
Lymphatic Drainage from Renal Tumors In Vivo: A Prospective Sentinel Node Study Using SPECT/CT ImagingTeele Kuusk, Roderick De Bruijn, Oscar R Brouwer, et al.
European Urology Open Science|September 11, 2023
Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?Elisabeth E Fransen van de Putte, Luna van den Brink, Mohamed A Mansour, et al.
Scandinavian Journal of Urology|December 12, 2018
Outcome of sentinel lymph node biopsy in patients with clinically non-metastatic renal cell carcinomaTeele Kuusk, Roderick De Bruijn, Oscar R Brouwer, et al.
Cancers|September 24, 2020
Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC TreatmentJudy R van Beijnum, Andrea Weiss, Robert H Berndsen, et al.
BJU International|July 7, 2025
Natural history of treated and untreated renal oncocytoma: a systematic review and meta-analysisFrancesco Edwards, Jack B Fanshawe, Joana Neves, et al.
European Urology|March 21, 2025
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 UpdateAxel Bex, Yasmin Abu Ghanem, Laurence Albiges, et al.
European Urology|December 16, 2022
Reply to Yaxiong Tang, Xu Hu, Kan Wu, Yanxiang Shao, and Xiang Li's Letter to the Editor re: Umberto Capitanio, Jens Bedke, Laurence Albiges, et al. A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel. Eur Urol. 2022;83:3-5Umberto Capitanio, Jens Bedke, Laurence Albiges, et al.
The Lancet. Oncology|October 2, 2025
Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer ConsortiumJames P Blackmur, J C Koen van der Mijn, Anne Y Warren, et al.
European Urology|June 2, 2021
The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of CareJens Bedke, Laurence Albiges, Umberto Capitanio, et al.
European Urology|November 26, 2022
European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist's Point of ViewMilan Hora, Laurence Albiges, Jens Bedke, et al.
Pageof 34

Showing results (251-260 of 332) with videos related to

Sort By:
Pageof 34
The Journal of Urology|December 11, 2017
Lymphatic Drainage from Renal Tumors In Vivo: A Prospective Sentinel Node Study Using SPECT/CT ImagingTeele Kuusk, Roderick De Bruijn, Oscar R Brouwer, et al.
European Urology Open Science|September 11, 2023
Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?Elisabeth E Fransen van de Putte, Luna van den Brink, Mohamed A Mansour, et al.
Scandinavian Journal of Urology|December 12, 2018
Outcome of sentinel lymph node biopsy in patients with clinically non-metastatic renal cell carcinomaTeele Kuusk, Roderick De Bruijn, Oscar R Brouwer, et al.
Cancers|September 24, 2020
Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC TreatmentJudy R van Beijnum, Andrea Weiss, Robert H Berndsen, et al.
BJU International|July 7, 2025
Natural history of treated and untreated renal oncocytoma: a systematic review and meta-analysisFrancesco Edwards, Jack B Fanshawe, Joana Neves, et al.
European Urology|March 21, 2025
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 UpdateAxel Bex, Yasmin Abu Ghanem, Laurence Albiges, et al.
European Urology|December 16, 2022
Reply to Yaxiong Tang, Xu Hu, Kan Wu, Yanxiang Shao, and Xiang Li's Letter to the Editor re: Umberto Capitanio, Jens Bedke, Laurence Albiges, et al. A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel. Eur Urol. 2022;83:3-5Umberto Capitanio, Jens Bedke, Laurence Albiges, et al.
The Lancet. Oncology|October 2, 2025
Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer ConsortiumJames P Blackmur, J C Koen van der Mijn, Anne Y Warren, et al.
European Urology|June 2, 2021
The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of CareJens Bedke, Laurence Albiges, Umberto Capitanio, et al.
European Urology|November 26, 2022
European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist's Point of ViewMilan Hora, Laurence Albiges, Jens Bedke, et al.
Pageof 34